Article Text
Letter
Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
Statistics from Altmetric.com
I read with great interest the excellent cost effectiveness analysis of pegylated interferon alpha 2b and ribavirin combination in patients with chronic hepatitis C (
). I was surprised by the relatively low cost of treatment initiation in Germany (table 3). The cost estimate of pre-therapeutic …
Footnotes
-
Conflict of interest: T Poynard has participated in clinical trials for viral hepatitis and as an advisor with the following companies: BMS, Boehringer, Gilead Science, GlaxoSmithKline, Idenix, Roche, and Schering Plough. He is a consultant and has financial participation in the capital of Biopredictive (start up company from Bioincubator ParisBiotech, University Paris 5), which is is marketing Fibrotest and Actitest.